NasdaqCM:ALQA

Stock Analysis Report

Executive Summary

Alliqua BioMedical, Inc. develops, manufactures, and markets high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.


Similar Companies

Share Price & News

How has Alliqua BioMedical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

263.7%

ALQA

1.9%

US Medical Equipment

0.4%

US Market


1 Year Return

-39.4%

ALQA

15.6%

US Medical Equipment

6.9%

US Market


Shareholder returns

ALQAIndustryMarket
7 Day263.7%1.9%0.4%
30 Day-45.4%-1.7%-1.1%
90 Day-36.0%-0.03%-0.5%
1 Year-0.5%-39.4%16.5%15.6%9.3%6.9%
3 Year-72.6%-83.3%72.1%66.9%45.8%36.4%
5 Year-96.4%-97.8%125.8%100.8%62.9%45.1%

Price Volatility Vs. Market

How volatile is Alliqua BioMedical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Alliqua BioMedical undervalued compared to its fair value and its price relative to the market?

1.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate ALQA's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ALQA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALQA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: ALQA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate ALQA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALQA is good value based on its PB Ratio (1x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Alliqua BioMedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.1%

Forecasted Healthcare industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALQA's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if ALQA's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ALQA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ALQA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Alliqua BioMedical performed over the past 5 years?

26.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ALQA is unprofitable, but has reduced losses over the past 5 years at a rate of 26.5% per year.

Accelerating Growth: Unable to compare ALQA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALQA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: ALQA has a negative Return on Equity (-85.89%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ALQA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ALQA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Alliqua BioMedical's financial position?


Financial Position Analysis

Short Term Liabilities: ALQA's short term assets ($8.1M) exceeds its short term liabilities ($975.0K)

Long Term Liabilities: ALQA's short term assets (8.1M) exceeds its long term liabilities (1.8M)


Debt to Equity History and Analysis

Debt Level: ALQA's debt to equity ratio (13.6%) is considered satisfactory

Reducing Debt: ALQA's debt to equity ratio has increased from 0% to 13.6% over the past 5 years.


Balance Sheet

Information is not available.

Information is not available.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALQA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ALQA has less than a year of cash runway if free cash flow continues to grow at historical rates of 35.7% each year.


Next Steps

Dividend

What is Alliqua BioMedical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ALQA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ALQA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ALQA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALQA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALQA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Alliqua BioMedical's salary, the management and board of directors tenure and is there insider trading?

6.9yrs

Average board tenure


CEO

Dave Johnson (60yo)

6.3yrs

Tenure

US$911,900

Compensation

Mr. David Ian Johnson, also known as Dave, has been the Chief Executive Officer and President at Alliqua BioMedical, Inc. since February 4, 2013. Mr. Johnson has been Principal Financial Officer of Alliqua ...


CEO Compensation Analysis

Information is not available.

Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

6.9yrs

Average Tenure

60.5yo

Average Age

Experienced Board: ALQA's board of directors are considered experienced (6.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Dave Johnson (60yo)

    President

    • Tenure: 6.3yrs
    • Compensation: US$911.90k
  • Phillip Forman (59yo)

    Executive Vice President of Clinical Affairs

    • Tenure: 0yrs

Board Members

  • Joe Leone (64yo)

    Director

    • Tenure: 8.3yrs
    • Compensation: US$50.44k
  • Michael Goldberg (59yo)

    Member of Scientific Advisory Board

    • Tenure: 7yrs
    • Compensation: US$3.60k
  • Mark Wagner (61yo)

    Director

    • Tenure: 4yrs
    • Compensation: US$41.07k
  • Gary Restani (71yo)

    Director

    • Tenure: 4.8yrs
    • Compensation: US$49.51k
  • Dave Johnson (60yo)

    President

    • Tenure: 6.3yrs
    • Compensation: US$911.90k
  • Steven Brigido

    Chairman of Scientific Advisory Board

    • Tenure: 6.8yrs
  • Harold Schoenhaus

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jeffrey Sklar (55yo)

    Director

    • Tenure: 8.3yrs
    • Compensation: US$51.07k
  • Michael Moore

    Member of Scientific Advisory Board

    • Tenure: 7yrs
  • Charles Wolff

    Member of Scientific Advisory Board

    • Tenure: 6.9yrs

Company Information

Alliqua BioMedical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alliqua BioMedical, Inc.
  • Ticker: ALQA
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$44.596m
  • Shares outstanding: 5.01m
  • Website: https://alliqua.com

Number of Employees


Location

  • Alliqua BioMedical, Inc.
  • 2150 Cabot Boulevard West
  • Suite B
  • Langhorne
  • Pennsylvania
  • 19047
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALQANasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDSep 2007
HL1BDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2007

Biography

Alliqua BioMedical, Inc. develops, manufactures, and markets high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/05/07 07:58
End of Day Share Price2019/05/06 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.